Selected article for: "care unit and primary endpoint"

Author: Bean, Daniel; Kraljevic, Zeljko; Searle, Thomas; Bendayan, Rebecca; Pickles, Andrew; Folarin, Amos; Roguski, Lukasz; Noor, Kawsar; Shek, Anthony; o'gallagher, Kevin; Zakeri, Rosita; Shah, Ajay; Teo, James; Dobson, Richard JB
Title: Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust
  • Cord-id: 60wcvkbn
  • Document date: 2020_4_11
  • ID: 60wcvkbn
    Snippet: Abstract: Background: The SARS-Cov2 virus binds to the ACE2 receptor for cell entry. It has been suggested that ACE-inhibitors, which are commonly used in patients with hypertension or diabetes and which raise ACE2 levels, may increase the risk of severe COVID-19 infection. Methods: We evaluated this hypothesis in an early cohort of 205 acute inpatients with COVID-19 at King's College Hospital and Princess Royal University Hospital, London, UK with the primary endpoint being death or transfer to
    Document: Abstract: Background: The SARS-Cov2 virus binds to the ACE2 receptor for cell entry. It has been suggested that ACE-inhibitors, which are commonly used in patients with hypertension or diabetes and which raise ACE2 levels, may increase the risk of severe COVID-19 infection. Methods: We evaluated this hypothesis in an early cohort of 205 acute inpatients with COVID-19 at King's College Hospital and Princess Royal University Hospital, London, UK with the primary endpoint being death or transfer to a critical care unit for organ support within 7-days of symptom onset. Findings: 53 patients out of 205 patients reached the primary endpoint. Contrary to the hypothesis, treatment with ACE-inhibitors was associated with a reduced risk of rapidly deteriorating severe disease. There was a lower rate of death or transfer to a critical care unit within 7 days in patients on an ACE-inhibitor OR 0.29 (CI 0.10-0.75, p<0.01), adjusting for age, gender, comorbidities (hypertension, diabetes mellitus, ischaemic heart disease and heart failure). Interpretation: Although a small sample size, we do not see evidence for ACE-inhibitors increasing the short-term severity of COVID-19 disease and patients on treatment with ACE-inhibitors should continue these drugs during their COVID-19 illness. A potential beneficial effect needs to be explored as more data becomes available.

    Search related documents:
    Co phrase search for related documents
    • ace inhibition and active research: 1
    • ace inhibition and acute lung injury: 1, 2, 3
    • ace inhibition and acute lung injury protective: 1
    • ace inhibition and acute respiratory: 1, 2, 3, 4, 5, 6
    • ace inhibition and acute respiratory distress syndrome: 1
    • ace inhibition and lung injury: 1, 2, 3, 4
    • ace inhibitor and acei ace inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • ace inhibitor and acei ace inhibitor treatment: 1, 2
    • ace inhibitor and acute lung injury: 1, 2, 3, 4
    • ace inhibitor and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
    • ace inhibitor and acute respiratory distress syndrome: 1, 2, 3, 4, 5
    • ace inhibitor and admission death: 1, 2
    • ace inhibitor and admission need: 1
    • ace inhibitor and logistic regression: 1, 2, 3, 4, 5, 6, 7
    • ace inhibitor and logistic regression model: 1, 2
    • ace inhibitor and lung injury: 1, 2, 3, 4
    • ace inhibitor disease severity increase and acute respiratory: 1
    • ace inhibitor exposure and logistic regression: 1